Switchpoint Bio has raised €4.75 million in pre-Seed financing aimed at enhancing its blood-based epigenomic platform. This funding, which includes a substantial €4.48 million investment from Treehouse Delmar Investments, is expected to aid the company in transforming how drug developers understand disease responses and treatment effects in patients.
The Helsinki- and Cambridge-based startup was founded by PhD researchers from Stanford University, including MacArthur Fellow Jason Buenrostro and Samuel Myllykangas, who previously scaled Blueprint Genetics. Their innovative approach uses circulating immune cells that reflect epigenomic changes, providing drug developers vital insights into therapeutic strategies.
Following this significant funding, Switchpoint Bio is positioned to advance its technology, which could transform drug response analysis in the pharmaceutical industry.
